![]() Music |
![]() Video |
![]() Movies |
![]() Chart |
![]() Show |
![]() |
ACC 2018: SGLT-2 Inhibitors Versus Other Glucose Lowering Drugs (Radcliffe Cardiology) View |
![]() |
Cardiovascular Outcomes in New Users of SGLT-2 Inhibitors (Radcliffe Cardiology) View |
![]() |
Choosing SGLT2 Inhibitors vs GLP-1 Receptor Agonists (Harvard Medical School Continuing Education) View |
![]() |
SGLT2 Inhibitors and Heart Failure (Harvard Medical School Continuing Education) View |
![]() |
ACC 2021 Discussion: Benefits of SGLT1/2 Inhibition Across the Full Spectrum of EF (Radcliffe Cardiology) View |
![]() |
What's New in Prevention From ACC.18 (American College of Cardiology) View |
![]() |
SGLT2 Inhibition and the Prevention of MACEs (AJMCtv MJH) View |
![]() |
Update on SGLT-2 inhibitors (ADA 2021) (GoggleDocs Education) View |
![]() |
Current CV Evidence Across SGLT2 Inhibitors (HCPLive) View |
![]() |
SGLT2 Inhibition and CVD Outcomes in Type 2 Diabetes (AJMCtv MJH) View |